Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04824118
Other study ID # AC20164
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 26, 2021
Est. completion date August 12, 2021

Study information

Verified date April 2022
Source NHS Lothian
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Venous thromboembolism (VTE - blood clots that form in deep veins or in the lungs) has been identified as a leading cause of death in economically developed countries for pregnant and recently-pregnant women. There is evidence that clotting parameters can take up to 6 weeks to return to normal for women who have had term deliveries, however there is an absence of information on time taken for clotting parameters to normalise following abortion. As such, existing guidelines are based solely on expert opinion and recommend durations of VTE prevention from as short as 7 days, up to 6 weeks following abortion. All women are assessed for risk of VTE, but data are needed to inform an evidence-based approach to prevention of VTE in these women. The findings from this pilot study have the potential to inform clinical guidance and possibly a larger study subsequently.


Description:

Sample population: Women who attend the abortion service at the Chalmers Centre to receive abortion assessment and abortion care. There will be 3 groups recruited based upon gestational age of pregnancy - Group 1: Gestation less than 10 weeks (10 participants), Group 2: Gestation 10+0 -13+6 weeks (10 participants), Group 3: Gestation 14+0-20+0 weeks (10 participants). Information Sheet: All new patients attending the clinic will be given a copy of the participant information sheet, so that they have time to read about the study. The Information sheet will also be available on the 'research' section of the clinic website - all women are routinely directed to this page before attending clinic. Approach by research staff: Following registration, all patients are taken for an ultrasound scan by a clinical support worker to confirm gestation. Following this, patients move to a waiting area until they can be seen for their assessment. While they are waiting, the clinic coordinator will ask the patient if they are happy to be approached by the researcher to discuss the study further. If they are happy to discuss further, the researcher will then approach and discuss the study in a private room. Consent: If patients are happy to participate in the study, the researcher will then obtain written informed consent prior to their bloods being taken by clinic staff if bloods required for routine care, if no routine bloods are required, the researcher will obtain the blood sample. Participants will be asked if they are planning to use a hormonal form of contraception following their abortion - if yes, they would be asked to wait until they have had their second blood sample taken to commence or not taken forward into the study. First blood test: This will be obtained on the day of clinic attendance and ultrasound scan. Blood samples (less than 20 ml) will be obtained and taken to the NHS Lothian laboratory at the Royal Infirmary of Edinburgh and for ClotPro thromboelastography point of care testing. Second blood test: An appointment will be made to see the patient in Chalmers Centre or at their home to obtain a further blood sample to compare to the initial test. This will take place 10-14 days following mifepristone administration. For the repeat sample we will conduct a COVID-19 risk assessment and only invite them for return visit/home visit if: 1. The participant has confirmed they and close contacts are well and without suspicion of COVID-19. 2. The participant agrees to a home visit. 3. The research staff undertaking the home visit should be well and have had no known contact with a COVID-19 positive individual for the past 14 days. If they are having an intrauterine contraceptive, implant or injection, the second blood sample can be taken when they come into clinic for this, to minimise the number of visits. Comparison group: A comparison group, Group 4 (10 participants), who are healthy volunteers, recruited from sexual and reproductive health clinics at Chalmers Centre, will be asked to provide a single blood test for ClotPro and lab tests, and urine pregnancy test hCG to act as a nonpregnant comparison. These participants must not be using hormonal contraception and must not be pregnant. This group will be approached by clinicians working in the SRH clinics and the researcher will be on hand to obtain consent and then draw blood.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date August 12, 2021
Est. primary completion date August 12, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria: Group 1: - Pregnant and seeking abortion - Gestation of pregnancy less than 10 weeks - Healthy, no medical conditions Group 2: - Pregnant and seeking abortion - Gestation of pregnancy between 10 and 14 weeks - Healthy, no medical conditions Group 3: - Pregnant and seeking abortion - Gestation of pregnancy between 14 to 20 weeks - Healthy, no medical conditions Group 4: - Non pregnant - Healthy, no medical conditions - Able to speak English independently Exclusion Criteria: All groups: - Unable to give informed consent - Previous or current venous thromboembolism - Current smoker - Personal or family history of thrombophilia or haemophilia - Taking medicines known to affect clotting parameters (e.g. Aspirin) Groups 1-3: - Planning to commence hormonal contraception prior to second blood test. Group 4: - Using hormonal contraception at baseline visit

Study Design


Intervention

Diagnostic Test:
Thromboelastometry
Point of Care Test for clotting parameters (ClotPro device)
Clotting Studies
Standard laboratory tests for clotting: International normalised ratio (INR) Prothrombin time (PT) adjusted partial thromboplastin time (aPTT) fibrinogen
Full Blood Count
For platelet count
Quantitative hCG
Serum human chorionic gonadotrophin
Pregnancy Test
Point of care urinary pregnancy test

Locations

Country Name City State
United Kingdom Chalmers Centre for Sexual and Reproductive Health Edinburgh

Sponsors (2)

Lead Sponsor Collaborator
NHS Lothian University of Edinburgh

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clotting Time in Seconds As measured using ClotPro device between baseline and follow up for Groups 1-3. 10-14 days
Primary Clot Formation Time in Seconds As measured using ClotPro device between baseline and follow up for Groups 1-3. 10-14 days
Primary Maximal Amplitude in millimeters On clotting curve as measured using ClotPro device between baseline and follow up for Groups 1-3. 10-14 days
Primary Maximum Lysis of clot in percentage As measured using ClotPro device between baseline and follow up for Groups 1-3. 10-14 days
Primary Clot Lysis index in percentage As measured using ClotPro device between baseline and follow up for Groups 1-3. 10-14 days
Primary Lysis time in seconds As measured using ClotPro device between baseline and follow up for Groups 1-3. 10-14 days
Secondary Prothrombin Time in seconds Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. 10-14 days
Secondary Activated Partial Thromboplastin Time in seconds Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. 10-14 days
Secondary International Normalised Ratio (INR) Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. 10-14 days
Secondary Fibrinogen in grams per litre Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. 10-14 days
Secondary Platelet count (x10^9 per litre) Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. 10-14 days
Secondary Thromboelastography parameters (comparison with non-pregnant group) Comparison of thromboelastography parameters (as measured using ClotPro device) between Groups 1-3 with Group 4. 10-14 days
Secondary Serum hCG in units per litre Comparison of serum hCG levels between baseline and follow up in groups 1-3 10-14 days
Secondary Lysis time in seconds As measured using ClotPro device between baseline and follow up for Groups 1-3. 10-14 days
Secondary Clot Lysis index in percentage As measured using ClotPro device comparing Groups 1-3 with Group 4 10-14 days
Secondary Maximum Lysis of clot in percentage As measured using ClotPro device comparing Groups 1-3 with Group 4 10-14 days
Secondary Maximal Amplitude in millimeters As measured using ClotPro device comparing Groups 1-3 with Group 4. 10-14 days
Secondary Clot Formation Time in Seconds As measured using ClotPro device comparing Groups 1-3 with Group 4 10-14 days
Secondary Clotting Time in Seconds As measured using ClotPro device comparing Groups 1-3 with Group 4 10-14 days
See also
  Status Clinical Trial Phase
Recruiting NCT05347550 - Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients N/A
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Completed NCT02379806 - The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study Phase 3
Recruiting NCT03691753 - Safety and Efficacy Study of Fitaya Vena Cava Filter N/A
Completed NCT02197416 - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Phase 3
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT01895777 - Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Phase 3
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Completed NCT04735523 - Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Completed NCT04736420 - Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Completed NCT04736719 - Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Completed NCT02912234 - Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants Phase 1
Completed NCT02746185 - Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban Phase 3
Completed NCT02829957 - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Phase 2/Phase 3
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02661568 - Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES) N/A
Completed NCT02223260 - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Phase 2
Completed NCT01972243 - Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
Completed NCT01431456 - Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery Phase 3